A negative allosteric modulator modulates GABAB-receptor signalling through GB2 subunits.


An γ-aminobutyric acid type B (GABAB)-receptor mediates slow and prolonged synaptic inhibition in the central nervous system, which represents an interesting target for the treatment of various diseases and disorders of the central nervous system. To date, only one activator of the GABAB-receptor, baclofen, is on the market for the treatment of spasticity… (More)
DOI: 10.1042/BJ20150979


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.